It has been recognized early that the race to produce COVID-19 vaccines will not halt the pandemic unless there is a general acceptance by the public to take the vaccine (Neumann-Böhme et al., 2020; Burgess et al., 2021). Therefore, COVID-19 vaccination hesitancy has been studied heavily before and since the early stage of vaccine availability, with high variation in the willingness to be vaccinated among different communities (Sallam, 2021; Feleszko et al., 2021; Lin et al., 2020). Several large multinational studies on vaccine acceptance have been conducted in 19 countries (n = 13,426) (Lazarus et al., 2021), 15 countries (n = 18,526) (Ipsos, 2020), 15 countries (n = 13,500) (Mega, 2021), 14 countries (n = 12,777) (Ipsos, 2021), and seven countries (n = 7662) (Neumann-Böhme et al., 2020). Interestingly, none of which covered Arabic-speaking nations. A smaller multinational study that surveyed 3414 participants was conducted in Jordan and Kuwait, with minor participation from some other Arab countries (Sallam et al., 2021). This study showed that vaccine acceptance was low (29.4%) and was lower in females, individuals with lower academic education, and individuals with no chronic diseases.

Other studies have been conducted in Saudi Arabia (n = 1000) and (n = 3101) (Al-Mohaithef and Padhi, 2020; Magadmi and Kamel, 2020), Egypt (n = 559) (Abdelhafiz et al., 2020), Jordan (n = 3100) (El-Elimat et al., 2020), and the UAE (n = 1109) (Muqattash et al., 2020). With the Arab nations having significant variations socioeconomically, politically and in the measures taken to control the pandemic, the study of reactions to and acceptance of the vaccine becomes necessary. Also, the authorization of the use of Sinopharm vaccine by some Arab countries, despite the lack of sufficient safety and effectiveness evidence (Cyranoski, 2020), may have an impact on the public’s trust in the vaccine and the health policies in these countries. Furthermore, attitudes toward the vaccines are affected by complex and dynamic interplaying factors, and considerable changes over time have been observed in acceptance and hesitancy rates (Lazarus et al., 2021; Ipsos, 2020; Mega, 2021; Ipsos, 2021; Wang et al., 2021; Imperial College London, 2021; Lewis, 2020). For all of these reasons, the earlier local studies cannot be generalized to the Arab world, and further larger studies will present a clearer picture of the region.

Arab countries and territories (23 in total) span a large geographical area in North Africa and West Asia with a population of over 440 million (Worldometer, 2021). The total reported number of COVID-19 cases in the region until the mid-February 2021 was more than 4.1 million with 70.7 thousand deaths (Dong et al., 2020; Appendix 1—figure 1). Yet, the Arab region is understudied, despite the geographical spread, the number of residents, and the number of cases and deaths. So, a large-scale multinational study for this area is necessary.

Our study aims to fill the gaps by investigating vaccine acceptance using a large-scale survey targeting the relatively understudied Arab populations living in different countries around the world following vaccine availability and administration. Secondly, to unveil the barriers leading to vaccine hesitancy and their prevalence among the participants using an extensive updated list of barriers against vaccine acceptance. Thirdly, the study compares the answers of the respondents residing in and outside the Arab world to evaluate the effect of socioeconomic, cultural, health policies and political differences on their reported attitudes and barriers to acceptance.

The Survey of Arab COVID-19 Vaccine Acceptance (SACVA) is an open online survey that was conducted using the online platform https://www.surveyplanet.com/ from 14 January 2021 to 29 January 2021. The sample population was a convenience sample targeted through a digital campaign using social media platforms. Institutional Review Board (IRB) approval was obtained from the last author’s institution. Unique IP addresses are allowed to participate once on the survey platform to prevent multiple entries. Consent to participate was obtained at the first entry of the survey portal for each participant. The platform allows participants to move through screens only when answers were obtained, which prevents missing entries. The survey consisted of 17 questions, including the consent to participate. All questions were written and validated in the Arabic language – an English translation of the questions can be found on Supplementary file 1. Questions two to nine captured demographics and current health status; question 10 was about the annual influenza vaccine; question 11 was about available vaccine(s) in each country (if known), and answers to subsequent questions were directed based on the type of available vaccine(s). Questions 12 and 13 queried whether the participant received the COVID-19 vaccination and if they had any side effects. Those who had already taken the vaccine were not allowed to answer question 14 that queried participant’s acceptance/hesitance toward COVID-19 vaccine; these participants were not included in the analysis reported in this paper. Questions 15 and16 surveyed participants' attitudes toward the need for COVID-19 vaccination and associated health policies. Question 17 was a detailed question that evaluated 29 barriers, which potentially influenced the decision to receive the vaccine in addition to ‘I do not have any reservations about taking the vaccine’ option. We also allowed participants who answered ‘Yes’, meaning they are willing to be vaccinated, to choose from the 29 barriers.

Questions were discussed thoroughly among authors and other colleagues. Face validity was tested by the third author, who has expertise in the domain. A pilot survey was then posted online and 100 individuals participated following direct contacts by authors. Analyzing responses and comments of this pilot survey helped in refining the final survey and confirming its validity and reliability.

The survey data was analyzed using R software v.4.0.2. Descriptive statistics and analytical graphs were used as needed. Participants were also subcategorized based on country of residence. Arab countries with less than 100 participants (Somalia, Djibouti, and Comoros) were grouped together in one category and labeled ‘Other Arab countries’. The non-Arab countries where the Arabic-speaking respondents were residing were classified into groups: European countries (n = 30), North American countries (n = 3), Turkey, and the rest of non-Arab countries as others (n = 88). The answers to the 14th question, ‘Do you intend to take the vaccine?’, were used as a dependent variable and were analyzed using binary logistic regression. Two of the answer choices (‘Yes’, ‘Depends on the type of vaccine’) were used to define vaccine acceptance, while the other three (‘No’, ‘Not sure’, ‘I will wait and see its effects on others’) were labeled as ‘Vaccine Hesitancy’. Responses to the question of the barriers to acceptance (Question 17) were compared for gender, academic education, and country of residence using chi-square. Our acquisition and analysis of the results followed the guidelines of the CHERRIES checklist (Eysenbach, 2004).

As for COVID-19 cases and death statistics, we used the COVID19 package v2.3.2 that collects data from different sources to provide up-to-date COVID-19 statistics (Guidotti and Ardia, 2020). The total number of confirmed cases and deaths were correlated with vaccine acceptance in different Arab countries using the Spearman correlation. The results of the survey can be found on the project’s website at https://mainapp.shinyapps.io/CVHAA, while the data and the R code written for the analysis can be found on the project’s GitHub repository (Qunaibi, 2021).

This study presents the largest online survey on vaccine hesitancy that covered a heterogeneous population of Arabic people living all over the globe. In addition, it bridged the gap in knowledge on vaccine hesitancy in the Arab region. It shows low rates of vaccine acceptance in the face of the ongoing pandemic. Only one in eight respondents (12.5%) reported their willingness to take the vaccine. One in 22 (4.4%) based their decision on whether to take the vaccine or not on the type of the vaccine, acknowledging that the vaccine type they prefer may not be available in the near future and even when available, they may not be given the choice of selecting that vaccine type. These results are of unique significance because the study has been conducted after the vaccine has become available and administered to millions of people worldwide, and while about 70 different vaccine candidates are currently under development.

The study also showed a clear correlation between acceptance and gender, academic background, attitudes toward the flu shot, having been previously suspected of – or confirmed with – COVID-19 infection and knowledge of the vaccine type. Females were more hesitant to take the vaccine, while the previous studies were inconclusive on the correlation of hesitance with gender, where women were found to have higher (Fisher et al., 2020; Grech et al., 2020; Kreps et al., 2020), equal (Abdelhafiz et al., 2020), or lower (Lazarus et al., 2021; Ward et al., 2020) hesitancy compared with men. Our results show lower acceptance in participants with current or previous suspected or confirmed COVID-19 infection (data) when compared with Lazarus et al. (n = 13,426) who found no significant correlation (Lazarus et al., 2021). On the other hand, our results are consistent with the literature in terms of lower acceptance in people who do not get influenza vaccination (Lin et al., 2020) and who have lower academic education (Lin et al., 2020; Lazarus et al., 2021).

Respondents who did not know the vaccine type available to them showed increased hesitancy. This may be attributed to the fact that some Arab countries were first to approve the Sinopharm vaccine despite lack of affirmative data (Cyranoski, 2020). The impact of vaccine efficacy on attitudes toward vaccination has been echoed in the study of Harapan et al. (n = 1359) (Harapan et al., 2020), conducted before vaccine availability, where 93.3% of respondents chose to be vaccinated with a 95% effective vaccine, but this acceptance rate decreased to 67.0% in the case of a vaccine with 50% effectiveness. The results showed a level of mistrust in health care policies in Arab countries (44%) which can also be attributed to the selection of certain vaccines, as well as the inability to choose which vaccine to take. All of these factors may contribute to high hesitance when the vaccine type is unknown to the participant.

Consistent with previous studies (Harapan et al., 2020; Detoc et al., 2020), HCW were more accepting the vaccine, although with still low proportions of about one in four (18% yes and 7.1% depending on the type). One study on Congolese HCW (n = 613) conducted in March–April, 2020 reported a similar notably low rate of acceptance (only 27.7%) (Kabamba Nzaji et al., 2020). In addition, consistent with the results of the multinational study by Lazarus et al. (n = 13,426) (Lazarus et al., 2021), participants from countries with higher per million COVID-19 cases were more likely to welcome the vaccine. Participants between the ages of 30 and 59 were less willing to receive vaccination compared with older participants, an expected result given the fact that COVID-19 severity is associated with older age. However, younger participants (<29 years old) showed more willingness to be vaccinated.

Among the 29 different reasons for vaccine rejection/hesitancy, the top two reasons selected by the respondents reflected concerns about safety, while the next three most prevalent reasons were issues of distrust. This is consistent with the literature, which showed high levels of distrust and concern about safety (Lin et al., 2020).

The three forms of distrust (in health care policies, in vaccine expedited production and in published studies) were notably higher among respondents residing in the Arab countries than those living outside the Arab world. The same applies to the belief that the vaccine has not been tested on a large enough number of people, just tens or hundreds, which reflects less awareness of the vaccine development process in the Arab countries and highlights the need to educate the general public on the subject. Similarly, more residents of the Arab world believe that the vaccine is not necessary anymore because most people in the participant’s country ‘have already been infected’ or because the infection rate is decreasing. The infection rate is in fact decreasing (Appendix 1—figure 1A), but the public may need to be made aware that future outbreaks are still a possibility.

With the high rate of distrust, any form of coercion to take the vaccine may have negative impacts. Lazarus et al.’s large-scale study indicated that promoting voluntary acceptance is a better route and that coercion should be avoided (Lazarus et al., 2021). Similarly, a systematic review indicated that ‘mandates could increase resistance' (Lin et al., 2020). In our study, the majority of participants (59.5%) believed that vaccination should be left to individual choices and only a minority believed it should be mandated for certain categories of people (6.1%) or on populations in which the vaccine was proven to be effective and safe as per clinical studies (13.6%).

Approximately one-fifth of our respondents chose ‘The vaccine might lose its efficacy against the new viral strains’ as a reason for hesitation. The survey was published shortly after reports of the new viral strains in the UK and South Africa have been made public, and with the recent reports of decreased efficacy of some vaccines (Kabamba Nzaji et al., 2020; The Guardian, 2021; Knoll and Wonodi, 2021), this concern of efficacy is expected to increase among the public.

Several factors appear to contribute to the low level of vaccine acceptance in the current study compared with the previous works. First of all, the response to the question of willingness is broken down from Yes/No or Likert scale (in previous works) to a spectrum of choices which could more accurately detect the hesitant respondents who could have otherwise chosen (Yes) or (Agree/Strongly agree). In a large-scale survey conducted in October 2020 that included 18,526 adults across 15 countries (Ipsos, 2020), 73% strongly agreed or agreed that ‘if a vaccine for COVID-19 were available, I would get it’. However, of those, only 22% agreed that they would become vaccinated ‘immediately after the vaccine is available’, while some others chose that they would wait for a year and even longer. The same study found out that there is less certainty about getting vaccinated among those who will wait. Thus, the affirmative nature of the Yes/No and 5-point Likert scales do not seem to reflect the true nature of hesitancy and whether or not it changes its nature over time.

In 2015, the World Health Organization (WHO) Strategic Advisory Group of Experts on Immunization defined vaccine hesitancy as a ‘delay in acceptance or refusal of vaccination despite the availability of vaccination services’ (MacDonald, 2015). We, therefore, question considering those who intend to take the vaccine after a prolonged time of availability as ‘Accepting’ since this may interfere with the targeted achievement of collective immunity.

In the present study, 20.8% of the participants chose (I will wait and see its effects on others) – many of whom could have possibly chosen (Yes) or (Agree) had the waiting choice been eliminated. A systematic review noted that ‘When answer options included different timings for vaccination, more people chose to wait than get it as soon as possible’ and that the two answer choices (Yes/No) received relatively high affirmatives (Lin et al., 2020). Only 3 of about 70 studies and polls in this review included the choice of ‘wait a while until others have taken it’ for the question of vaccine acceptance. In these three polls, conducted before vaccine availability, the percentage of those who chose that they would take the vaccine as soon as they can (or as soon as possible) was low (21–28%). This indicates that vaccine acceptance may be overestimated in many studies and highlights the need to redefine vaccine acceptance in a uniform way among different studies.

Another factor that may explain the lower rate of acceptance observed in the study is the nature of our survey population. Social and political differences were found to have a prominent effect on COVID-19 vaccine acceptance, especially that many people assumed political interference in the vaccine and in the pandemic itself (Lin et al., 2020). Vaccine acceptance was lower in Arab countries in previous studies: Jordan (37.4%) (El-Elimat et al., 2020), Saudi (64.72%) (Al-Mohaithef and Padhi, 2020) and (44.7%) (Magadmi and Kamel, 2020), and in a small multinational survey that included several countries, mainly Jordan and Kuwait (29.4%) (Sallam et al., 2021).

The chronological analysis of vaccine acceptance and time – in local and multinational studies – does not show a linear relationship – if anything, the public’s acceptance can be best described as fluctuating. Several surveys conducted in the last third of 2020 have shown a decrease in vaccination acceptance compared with previous surveys (Lin et al., 2020; Ipsos, 2020; Wang et al., 2021; Kreps et al., 2020). For example, the intent to vaccinate has declined in 10 of the 15 countries from August to October 2020 (Ipsos, 2020). A systematic review of publications until 20 October 2020 showed declining vaccine acceptance (from >70% in March to <50% in October) with demographic, socioeconomic, and partisan divides observed (Lin et al., 2020). However, a more recent multinational survey conducted from November 2020 to mid-January 2021 in 15 countries (Imperial College London, 2021) and a study conducted from 28 to 31 January 2020 in 14 countries Ipsos, 2021 have both shown an increase in vaccine acceptance.

As for Arab countries, the more recent studies (Sallam et al., 2021; El-Elimat et al., 2020; Hussein, 2021) show lower acceptance rates than the earlier ones. For example, A study conducted in Egypt (n = 559) during March 2020 found out that about 73.0% were looking forward to getting the vaccine when available (Al-Mohaithef and Padhi, 2020; Magadmi and Kamel, 2020; Abdelhafiz et al., 2020). However, the more recent study on HCW in Egypt (n = 496) during December 2020 concluded that only 13.5% totally agree to receiving the vaccine and 32.4% somewhat agree (Hussein, 2021). In our survey that is more recent than the mentioned studies, 17.0% and 24.0% of participants in Egypt (general [n = 5339] and HCW [n = 1250], respectively) were willing to take the vaccine.

A Saudi Arabia study published in May 2020 observed that 64.7% of participants (n = 1000) showed interest to accept the COVID-19 vaccine if it is available (Al-Mohaithef and Padhi, 2020), and another study conducted during May (n = 3101) showed a 44.7% acceptance rate (Magadmi and Kamel, 2020). However, in a more recent study in Saudi Arabia too, published in December 2020, 31.8% of participants (n = 154) showed acceptance (Sallam et al., 2021). In our survey that is more recent than the mentioned studies, 19.8% of participants from Saudi Arabia (n = 3588) showed acceptance.

Health care workers (HCWs) are at increased risk of acquiring and transmitting COVID-19 infection. Moreover, they present role models for communities with regards to attitudes towards COVID-19 vaccination. Therefore, vaccine hesitancy in this group is of a special concern, and we discussed hesitancy in Arab healthcare workers elsewhere (Qunaibi et al., 2021).

This study comes with few limitations. Similar to several previous surveys (Lin et al., 2020), participants were recruited through social media. Being an online survey, our study may have under-represented certain groups of individuals, including members of older age groups and those who are not active on social media. We cannot rule out selection bias that might have affected our results. Other high-risk groups such as people with chronic diseases are well represented (n = 5839) or even over-represented (HCW, n = 5708). Our sample size was not pre-planned but was rather arbitrary reflecting a convenience sample. We believe that the large number of participants and the consistency of results in different countries that were geographically close and similar socioeconomically confirm the reliability of our survey.

All data are available at our study website: https://mainapp.shinyapps.io/CVHAA. All the project's data and code has been deposited on Github. E. Qunaibi (2021) COVID-Vaccine-Arab-Survey. GitHub. https://github.com/MoHelmy/COVID-Vaccine-Arab-Survey. 5d1a881 (copy archived at https://archive.softwareheritage.org/swh:1:rev:5d1a8814d9dc1e3a87fb873ef994f9e0af2fce98).

1. 1. Abdelhafiz AS
   2. Mohammed Z
   3. Ibrahim ME
   4. Ziady HH
   5. Alorabi M
   6. Ayyad M
   7. Sultan EA

   (2020) Knowledge, Perceptions, and Attitude of Egyptians Towards the Novel Coronavirus Disease (COVID-19)

   Journal of Community Health 45:881–890.

   https://doi.org/10.1007/s10900-020-00827-7

   • Google Scholar
2. 1. Al-Mohaithef M
   2. Padhi BK

   (2020) Determinants of COVID-19 vaccine acceptance in Saudi Arabia: a Web-Based national survey

   Journal of Multidisciplinary Healthcare 13:1657–1663.

   https://doi.org/10.2147/JMDH.S276771

   • PubMed
   • Google Scholar
3. 1. Burgess RA
   2. Osborne RH
   3. Yongabi KA
   4. Greenhalgh T
   5. Gurdasani D
   6. Kang G
   7. Falade AG
   8. Odone A
   9. Busse R
   10. Martin-Moreno JM
   11. Reicher S
   12. McKee M

   (2021) The COVID-19 vaccines rush: participatory community engagement matters more than ever

   The Lancet 397:8–10.

   https://doi.org/10.1016/S0140-6736(20)32642-8

   • Google Scholar
4. 1. Cyranoski D

   (2020) Arab nations first to approve chinese COVID vaccine - despite lack of public data

   Nature 588:548.

   https://doi.org/10.1038/d41586-020-03563-z

   • PubMed
   • Google Scholar
5. 1. Detoc M
   2. Bruel S
   3. Frappe P
   4. Tardy B
   5. Botelho-Nevers E
   6. Gagneux-Brunon A

   (2020) Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic

   Vaccine 38:7002–7006.

   https://doi.org/10.1016/j.vaccine.2020.09.041

   • Google Scholar
6. 1. Dong E
   2. Du H
   3. Gardner L

   (2020) An interactive web-based dashboard to track COVID-19 in real time

   The Lancet Infectious Diseases 20:533–534.

   https://doi.org/10.1016/S1473-3099(20)30120-1

   • Google Scholar
7. 1. El-Elimat T
   2. AbuAlSamen MM
   3. Almomani BA
   4. Al-Sawalha NA
   5. Alali FQ

   (2020) Acceptance and attitudes toward COVID-19 vaccines: a cross-sectional study from jordan

   PLOS ONE 16:e0250555.

   https://doi.org/10.1371/journal.pone.0250555

   • Google Scholar
8. 1. Eysenbach G

   (2004) Improving the quality of web surveys: the checklist for reporting results of internet E-Surveys (CHERRIES)

   Journal of Medical Internet Research 6:e34.

   https://doi.org/10.2196/jmir.6.3.e34

   • PubMed
   • Google Scholar
9. 1. Feleszko W
   2. Lewulis P
   3. Czarnecki A
   4. Waszkiewicz P

   (2021) Flattening the Curve of COVID-19 Vaccine Rejection—An International Overview

   Vaccines 9:44.

   https://doi.org/10.3390/vaccines9010044

   • Google Scholar
10. 1. Fisher KA
    2. Bloomstone SJ
    3. Walder J
    4. Crawford S
    5. Fouayzi H
    6. Mazor KM

    (2020) Attitudes toward a potential SARS-CoV-2 vaccine : a survey of U.S. adults

    Annals of Internal Medicine 173:964–973.

    https://doi.org/10.7326/M20-3569

    • PubMed
    • Google Scholar
11. 1. Grech V
    2. Gauci C
    3. Agius S

    (2020) Withdrawn: vaccine hesitancy among maltese healthcare workers toward influenza and novel COVID-19 vaccination

    Early Human Development 2:105213.

    https://doi.org/10.1016/j.earlhumdev.2020.105213

    • Google Scholar
12. 1. Guidotti E
    2. Ardia D

    (2020) COVID-19 data hub

    Journal of Open Source Software 5:2376.

    https://doi.org/10.21105/joss.02376

    • Google Scholar
13. 1. Harapan H
    2. Wagner AL
    3. Yufika A
    4. Winardi W
    5. Anwar S
    6. Gan AK
    7. Setiawan AM
    8. Rajamoorthy Y
    9. Sofyan H
    10. Mudatsir M

    (2020) Acceptance of a COVID-19 Vaccine in Southeast Asia: A Cross-Sectional Study in Indonesia

    Frontiers in Public Health 8:381.

    https://doi.org/10.3389/fpubh.2020.00381

    • Google Scholar
14. Preprint

    1. Hussein MA

    (2021) National survey of potential acceptance of COVID-19 vaccines in healthcare workers in Egypt

    medRxiv.

    https://doi.org/10.1101/2021.01.11.21249324

    • Google Scholar
15. Website

    1. Imperial College London

    (2021) Confidence in coronavirus vaccines is rising globally, survey suggests | imperial news | imperial college London

    Accessed February 4, 2021.

    https://www.imperial.ac.uk/news/214074/confidence-coronavirus-vaccines-rising-globally-survey/
16. Website

    1. Ipsos

    (2020) COVID-19 vaccination intent is decreasing globally

    Accessed February 26, 2021.

    https://www.ipsos.com/en/global-attitudes-covid-19-vaccine-october-2020
17. Website

    1. Ipsos

    (2021) Global attitudes : covid-19 vaccines

    Accessed February 26, 2021.

    https://www.ipsos.com/en-us/global-attitudes-covid-19-vaccine-january-2021
18. 1. Kabamba Nzaji M
    2. Kabamba Ngombe L
    3. Ngoie Mwamba G
    4. Banza Ndala DB
    5. Mbidi Miema J
    6. Luhata Lungoyo C
    7. Lora Mwimba B
    8. Cikomola Mwana Bene A
    9. Mukamba Musenga E

    (2020) Acceptability of vaccination against COVID-19 among healthcare workers in the democratic republic of the Congo

    Pragmatic Obs Res 11:103–109.

    https://doi.org/10.2147/POR.S271096

    • Google Scholar
19. 1. Knoll MD
    2. Wonodi C

    (2021) Oxford–AstraZeneca COVID-19 vaccine efficacy

    The Lancet 397:72–74.

    https://doi.org/10.1016/S0140-6736(20)32623-4

    • Google Scholar
20. 1. Kreps S
    2. Prasad S
    3. Brownstein JS
    4. Hswen Y
    5. Garibaldi BT
    6. Zhang B
    7. Kriner DL

    (2020) Factors Associated With US Adults’ Likelihood of Accepting COVID-19 Vaccination

    JAMA Network Open 3:e2025594.

    https://doi.org/10.1001/jamanetworkopen.2020.25594

    • Google Scholar
21. 1. Lazarus JV
    2. Ratzan SC
    3. Palayew A
    4. Gostin LO
    5. Larson HJ
    6. Rabin K
    7. Kimball S
    8. El-Mohandes A

    (2021) A global survey of potential acceptance of a COVID-19 vaccine

    Nature Medicine 27:225–228.

    https://doi.org/10.1038/s41591-020-1124-9

    • PubMed
    • Google Scholar
22. 1. Lewis JR

    (2020) What is driving the decline in people’s Willingness to Take the COVID-19 Vaccine in the United States?

    JAMA Health Forum 1:e201393.

    https://doi.org/10.1001/jamahealthforum.2020.1393

    • Google Scholar
23. 1. Lin C
    2. Tu P
    3. Beitsch LM

    (2020) Confidence and Receptivity for COVID-19 Vaccines: A Rapid Systematic Review

    Vaccines 9:16.

    https://doi.org/10.3390/vaccines9010016

    • Google Scholar
24. 1. MacDonald NE

    (2015) Vaccine hesitancy: Definition, scope and determinants

    Vaccine 33:4161–4164.

    https://doi.org/10.1016/j.vaccine.2015.04.036

    • Google Scholar
25. 1. Magadmi RM
    2. Kamel FO

    (2020) Beliefs and barriers associated with COVID-19 vaccination among the general population in saudi arabia

    BMC Public Health 1:1–17.

    https://doi.org/10.21203/rs.3.rs-48955/v1

    • Google Scholar
26. 1. Mega ER

    (2021) Trust in COVID vaccines is growing

    Nature.

    https://doi.org/10.1038/d41586-021-00368-6

    • Google Scholar
27. 1. Muqattash R
    2. Niankara I
    3. Traoret RI

    (2020) Survey data for COVID-19 vaccine preference analysis in the united arab emirates

    Data in Brief 33:106446.

    https://doi.org/10.1016/j.dib.2020.106446

    • PubMed
    • Google Scholar
28. 1. Neumann-Böhme S
    2. Varghese NE
    3. Sabat I
    4. Barros PP
    5. Brouwer W
    6. van Exel J
    7. Schreyögg J
    8. Stargardt T

    (2020) Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19

    The European Journal of Health Economics 21:977–982.

    https://doi.org/10.1007/s10198-020-01208-6

    • Google Scholar
29. Software

    1. Qunaibi E

    (2021) COVID-Vaccine-Arab-Survey, version 5d1a881

    GitHub.

    https://github.com/MoHelmy/COVID-Vaccine-Arab-Survey
30. 1. Qunaibi E
    2. Basheti I
    3. Soudy M
    4. Sultan I

    (2021) Hesitancy of arab healthcare workers towards COVID-19 vaccination: a Large-Scale multinational study

    Vaccines 9:446.

    https://doi.org/10.3390/vaccines9050446

    • PubMed
    • Google Scholar
31. 1. Sallam M

    (2021) COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates

    Vaccines 9:160.

    https://doi.org/10.3390/vaccines9020160

    • PubMed
    • Google Scholar
32. 1. Sallam M
    2. Dababseh D
    3. Eid H
    4. Al-Mahzoum K
    5. Al-Haidar A
    6. Taim D
    7. Yaseen A
    8. Ababneh NA
    9. Bakri FG
    10. Mahafzah A

    (2021) High rates of COVID-19 vaccine hesitancy and its association with conspiracy beliefs: a study in Jordan and Kuwait among other arab countries

    Vaccines 9:42.

    https://doi.org/10.3390/vaccines9010042

    • PubMed
    • Google Scholar
33. Website

    1. The Guardian

    (2021) Oxford covid jab less effective against south african variant study finds | World news

    Accessed February 26, 2021.

    https://www.theguardian.com/world/2021/feb/07/oxford-covid-jab-less-effective-against-south-african-variant-study-finds
34. 1. Wang K
    2. Wong EL-Y
    3. Ho K-F
    4. Cheung AW-L
    5. Yau PS-Y
    6. Dong D
    7. Wong SY-S
    8. Yeoh E-K

    (2021) Change of Willingness to Accept COVID-19 Vaccine and Reasons of Vaccine Hesitancy of Working People at Different Waves of Local Epidemic in Hong Kong, China: Repeated Cross-Sectional Surveys

    Vaccines 9:62.

    https://doi.org/10.3390/vaccines9010062

    • Google Scholar
35. 1. Ward JK
    2. Alleaume C
    3. Peretti-Watel P
    4. COCONEL Group

    (2020) The french public's attitudes to a future COVID-19 vaccine: The politicization of a public health issue

    Social Science & Medicine 265:113414.

    https://doi.org/10.1016/j.socscimed.2020.113414

    • PubMed
    • Google Scholar
36. Website

    1. Worldometer

    (2021) Real time world statistics

    Accessed February 26, 2021.

    https://www.worldometers.info/

Acceptance summary:

The current SARS Cov-2 pandemic can only be effectively controlled by the delivery of effective vaccines to non-immune populations but a significant hurdle to this is vaccine hesitancy and the consequent failure to take up the offer of vaccination. To counter this public health authorities need to have robust data on the extent of vaccine rejection and the underlying reasons for this. The paper by Qunaibi and colleagues addresses this question in a large scale online study of over 36,000 participants from all the Arab speaking countries plus > 100 other countries with Arabs living in them. The data represent the largest study to date and the detailed questionnaires provide context behind the acceptance or rejection of a highly effective vaccine against a life threatening infectious disease. As one of the reviewers comments the study "provides important dataset for the health authorities in Arab and non-Arab countries to plan mitigation strategies to improve vaccine acceptance".

Decision letter after peer review:

Thank you for your submission entitled "A High Rate of COVID-19 Vaccine Hesitancy in a Large-scale Survey on Arabs". Your paper has been evaluated by two reviewers and by a Reviewing Editor and a Senior Editor. As is customary in eLife, the reviewers have discussed their critiques with one another and with the editors. We are pleased to inform you that your article has been accepted for publication in eLife.

Please take note of the points below, in case you may wish to revise the paper prior to production. We hope you will continue to support eLife.

Reviewer #1:

The authors conducted a large-scale online survey that covers the region of the Arab countries and the Arabic-speaking people residing outside the Arab region. The main focus of the survey is to assess the vaccination acceptance in the Arab region accurately and in details. The work has multiple strength points:

1. The large sample size. The authors successfully recruited over 36K participants which makes this survey the largest worldwide, to date.

2. The detailed differentiation between the levels of acceptance/hesitation came in 5 different detailed levels, unlike other surveys that make them from 1 to 10 or yes/no.

3. The very detailed reasoning of the vaccine hesitancy. The authors asked the participants to detail their reasons for hesitation or rejection by giving them 29 different reasons that cover almost all possible hesitancy reasons.

4. The study is the first multinational study in the region. The Arab region was not studied at all, except a few local studies with limited participation. So, this study comes to fill a gap in the data about the region.

The results of the survey show a high rate of vaccination hesitancy, which comes in agreement with the escalated rates worldwide post-vaccination campaigns and news about unexpected side effects.

Reviewer #2:

The manuscript "A High Rate of COVID-19 Vaccine Hesitancy 1 in a Large-scale Survey on Arabs" submitted by Eyad A. Qunaibi presents detailed description on hesitancy against COVID-19 vaccine with thorough analyses of factors influencing such hesitancy across the entire Arab world. The analysis conveniently included a small, yet reasonably-sized, sample of Arabs living in non-Arab countries, which provided a contrasting substance to compare with the main study. The manuscript is helpful in understanding the spectrum of barriers limiting people's acceptance of vaccination against COVID-19, and further highlights major barriers consistent with previously published literature, yet at a much larger scale.

Main barriers cluster around lack of knowledge that likely results in mistrust and worry. This is highlighted in the high proportion of participants not receiving the annual influenza vaccine and the concerns with the safety of COVID-19 particularly due to the speedy emergency use authorization of such vaccines.

One major value is the thoroughness of barriers included in the manuscript, which provides important dataset for the health authorities in Arab and non-Arab countries to plan mitigation strategies to improve vaccine acceptance.

The only optional recommendation that may improve on the quality of the manuscript, if data is available, is to understand similarities and differences in response to barriers between countries that show higher vs. lower hesitancy to COVID-19 vaccine. For example, was there a response pattern among Qatar, Oman, and Kuwait that clusters uniquely compared with response pattern among Tunisia, Algeria, and Morocco? Similarly, were there similar pattern of responses to barriers in countries with high acceptance such as in Qatar, Oman, and Kuwait compared with non-Arab countries of match acceptance such as North America? Such data may provide additional guiding details that will allow health authorities to devise more accurate policies to minimize such country-specific barriers and improve the rate of vaccine acceptance.

Reviewer #2:

[…] The only optional recommendation that may improve on the quality of the manuscript, if data is available, is to understand similarities and differences in response to barriers between countries that show higher vs. lower hesitancy to COVID-19 vaccine. For example, was there a response pattern among Qatar, Oman, and Kuwait that clusters uniquely compared with response pattern among Tunisia, Algeria, and Morocco? Similarly, were there similar pattern of responses to barriers in countries with high acceptance such as in Qatar, Oman, and Kuwait compared with non-Arab countries of match acceptance such as North America? Such data may provide additional guiding details that will allow health authorities to devise more accurate policies to minimize such country-specific barriers and improve the rate of vaccine acceptance.

Thank you for the nice recommendation. Per the reviewer’s comment, we compared the response to barriers between countries that show higher hesitancy (Algeria, Mauritania, Tunisia) vs. lower hesitancy (Kuwait, Oman, Qatar) to COVID-19 vaccine. We found that the most prominent difference was in choosing the following barrier:

“I do not trust the healthcare policies applied in my country”.

The response rate to this barrier was as follows:

Countries with high hesitancy: Algeria 51.7%, Mauritania 46.5%, Tunisia 38.8%.

Countries with low hesitancy: Kuwait 18.5%, Oman 16.6%, Qatar 4.7%.

Author details

1. Eyad A Qunaibi

   Faculty of Pharmacy, Jerash University, Jerash, Jordan

   Contribution

   Conceptualization, Data curation, Supervision, Investigation, Methodology, Writing - original draft, Literature survey

   For correspondence

   eyad.aqunaibi@jpu.edu.jo

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0003-0648-0757

2. Mohamed Helmy

   1. Computational Biology and Omics, Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), Biopolis, Singapore, Singapore
   2. Department of Computer Science, Lakehead University, Thunder Bay, Canada

   Contribution

   Software, Writing - original draft, Writing - review and editing

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-9561-7956

3. Iman Basheti

   Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan

   Contribution

   Conceptualization, Formal analysis, Validation, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

4. Iyad Sultan

   1. Department of Paediatrics, University of Jordan, Amman, Jordan
   2. Department of Paediatrics and Cancer Care Informatics Program, King Hussein Cancer Center, Amman, Jordan

   Contribution

   Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-2664-1565

• 17,026

  Page views

• 585

  Downloads

• 67

  Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.